<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443208</url>
  </required_header>
  <id_info>
    <org_study_id>B2061137</org_study_id>
    <nct_id>NCT01443208</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet</brief_title>
  <official_title>A Phase 1, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, Parallel-Group, Single and Multiple-Dose Study of Desvenlafaxine in Korean Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics and safety of single dose and multiple doses of
      desvenlafaxine in Korean healthy subjects and compare to westerners.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For single dose: maximum concentration (Cmax)</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For single dose: time to first occurence of Cmax (Tmax)</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For single dose: area under curve (0-time for last quantifiable concentration) (AUClast)</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For multiple dose: maximum concentration (Cmax)</measure>
    <time_frame>day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For multiple dose: time to first occurence of Cmax (Tmax)</measure>
    <time_frame>day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For multiple dose: trough concentration (Ctrough)</measure>
    <time_frame>day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For multiple dose: area under curve (0-24hours) (AUC0-24)</measure>
    <time_frame>day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>For single dose if data permit: terminal elimination half life (t1/2)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For single dose if data permit: area under curve (0-infinity) (AUCinf)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For single dose if data permit: oral clearance (CL/F)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For single dose if data permit: apparent volume of distribution (Vz/F)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For multiple dose if data permit: accumulation factor (Rac)</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For multiple dose if data permit: terminal elimination half life (t1/2)</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For multiple dose if data permit: oral clearance (CL/F)</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For multiple dose if data permit: apparent volume of distribution (Vz/F)</measure>
    <time_frame>day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desvenlafaxine</intervention_name>
    <description>one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days</description>
    <arm_group_label>50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desvenlafaxine</intervention_name>
    <description>one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days</description>
    <arm_group_label>100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desvenlafaxine</intervention_name>
    <description>two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days</description>
    <arm_group_label>200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects

          -  Between the ages of 18 and 55 years, inclusive

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

        Exclusion Criteria:

          -  Elevated risk of suicide, in the opinion of the investigator or expert consultant

          -  Pregnant or nursing females

          -  Females of childbearing potential who are unwilling or unable to use an acceptable
             method of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2061137&amp;StudyName=Pharmacokinetics%20and%20Safety%20of%20Desvenlafaxine%20in%20Korean%20Healthy%20Subjects%20Following%20Single%20and%20Multiple%20Oral%20Doses%20of%20Desvenlafaxine%20Succinat</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>desvenlafaxine</keyword>
  <keyword>Korean healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

